Abstract
Neuroimaging techniques play a central role in the diagnosis and management of Central nervous system (CNS) diseases. The use of Magnetic Resonance Imaging (MRI) has helped to diagnose and understand disease processes early on. The use of contrast media has improved visualization of normal and abnormal tissues. New developments in contrasat media agents have shown great promise: Goadobutrol, the first one molar paramagnetic contrast agent has shown to be of use in MR angiography and in perfusion of the brain while newer applications such as to the diagnosis of inflammatory diseases such as multiple sclerosis are promising. Another product, Gadofosveset (Vasovist®) is an intravascular MRI contrast agent that has shown to be of interest for imaging of vascular pathology as well as brain tumours. These two new MRI contrast media should allow expanding and strengthening the armamentarium at our disposal for the diagnosis and management of CNS diseases.
Similar content being viewed by others
References
Caravan P, Cloutier NJ, Greenfield MT, McDermid SA, Dunham SU, Bulte JW, Amedio JC Jr, Looby RJ, Supkowski RM, Horrocks WD Jr, McMurry TJ, Lauffer RB (2002) The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 124:3152–3162
Bluemke DA, Stillman AE, Bis KG, Grist TM, Baum RA, D’Agostino R, Malden ES, Pierro JA, Yucel EK (2001) Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology 219:114–122
Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, Mohler ER, 3rd (2003) MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. Radiology 229:811–8200
Goyen M, Shamsi K, Schoenberg SO (2006) Vasovistr-enhanced MR angiography. Eur Radiol 16[Suppl 2]:B9–B14
Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC (1998) MS-325: albumin-targeted contrast agent for MR angiography. Radiology 207:529–538
Nikolaou K, Kramer H, Grosse C, Clevert D, Dietrich O, Hartmann M, Chamberlin P, Assmann S, Reiser MF, Schoenberg SO (2006) Highspatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology 241:861–872
Ge Y (2006) Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 27:1165–1176
Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS (2006) Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 27:455–461
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069
Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernandez O, Seeldrayers P, Sorensen P, Margrie S, Rovaris M, Comi G, Filippi M (2003) Early Treatment of Multiple Sclerosis Study Group. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta 1a. Ann Neurol 53:718–724
Lemke AJ, Sander B, Balzer T, Geens V, Hosten N, Felix R (1997) Safety and use of gadobutrol in patients with brain tumors (phase III trial). Rofo 167:591
Essig M, Lodemann KP, Le-Huu M, Bruning R, Kirchin M, Reith W (2006) Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 41:256–263
Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, Wels T, Sorensen AG (2003) Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/l gadobutrol. Radiology 226:880–888
Benner T, Reimer P, Erb G, Schuierer G, Heiland S, Fischer C, Geens V, Sartor K, Forsting M (2000) Cerebral MR perfusion imaging: first clinical application of a 1-M gadolinium chelate (Gadovistr 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 12:371–380
Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R (1995) Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high-dose protocol. Intraindividual evaluation of a phase-II high-dose study (in German). Radiologe 35:508–516
Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Invest Radiol 40:715–724
Uysal E, Erturk SM, Yildirim H, Seleker F, Basak M (2007) Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5-M and 1.0-M gadolinium chelates for detecting multiple sclerosis lesions. AJR Am J Roentgenol 188:697–702
Haacke EM, Xu Y, Cheng YC, Reichenbach JR (2004) Susceptibility weighted imaging (SWI). Magn Reson Med 52:612–618
Reichenbach JR, Venkatesan R, Schillinger et al (1997) Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 204:272–277
Essig M, Reichenbach JR, Schad LR, et al (1999) High-resolution MR venography of cerebral arteriovenous malformations. Mag Res Imaging 17:1417–1425
Sehal V, Delproposto Z, Haacke EM, et al (2005) Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 22:439–450
Barth M, Noebauer-Huhmann IM, Reichenbach JR, et al (2003) High resolution, three dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first experience and comparison with 1.5 Tesla. Invest Radiol 38:409–414
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lövblad, KO., Essig, M. Head and Neck Imaging. Eur Radiol Suppl 18 (Suppl 5), 35–45 (2008). https://doi.org/10.1007/s10406-009-0244-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10406-009-0244-6